Could common pills boost cancer treatment? new melanoma trial investigates
NCT ID NCT05968690
Summary
This early-stage study is checking if it's safe to add two common, low-cost drugs—naltrexone and propranolol—to standard immunotherapy for advanced melanoma. The idea is that these drugs, which block the body's stress response, might help the immune system fight cancer better. Researchers will enroll about 12 patients to find the right dose and watch for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.